147 related articles for article (PubMed ID: 35954320)
1. Total Neoadjuvant Therapy for Rectal Cancer in the CAO/ARO/AIO-12 Randomized Phase 2 Trial: Early Surrogate Endpoints Revisited.
Diefenhardt M; Schlenska-Lange A; Kuhnt T; Kirste S; Piso P; Bechstein WO; Hildebrandt G; Ghadimi M; Hofheinz RD; Rödel C; Fokas E;
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954320
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials.
Diefenhardt M; Fleischmann M; Martin D; Hofheinz RD; Piso P; Germer CT; Hambsch P; Grützmann R; Kirste S; Schlenska-Lange A; Ghadimi M; Rödel C; Fokas E;
Radiother Oncol; 2023 Feb; 179():109455. PubMed ID: 36572280
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.
Fokas E; Fietkau R; Hartmann A; Hohenberger W; Grützmann R; Ghadimi M; Liersch T; Ströbel P; Grabenbauer GG; Graeven U; Hofheinz RD; Köhne CH; Wittekind C; Sauer R; Kaufmann M; Hothorn T; Rödel C;
Ann Oncol; 2018 Jul; 29(7):1521-1527. PubMed ID: 29718095
[TBL] [Abstract][Full Text] [Related]
4. Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer.
Fokas E; Ströbel P; Fietkau R; Ghadimi M; Liersch T; Grabenbauer GG; Hartmann A; Kaufmann M; Sauer R; Graeven U; Hoffmanns H; Raab HR; Hothorn T; Wittekind C; Rödel C;
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206996
[TBL] [Abstract][Full Text] [Related]
5. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial.
Fokas E; Liersch T; Fietkau R; Hohenberger W; Beissbarth T; Hess C; Becker H; Ghadimi M; Mrak K; Merkel S; Raab HR; Sauer R; Wittekind C; Rödel C
J Clin Oncol; 2014 May; 32(15):1554-62. PubMed ID: 24752056
[TBL] [Abstract][Full Text] [Related]
6. Overall Survival After Treatment Failure Among Patients With Rectal Cancer.
Diefenhardt M; Martin D; Fleischmann M; Hofheinz RD; Ghadimi M; Rödel C; Fokas E
JAMA Netw Open; 2023 Oct; 6(10):e2340256. PubMed ID: 37902752
[TBL] [Abstract][Full Text] [Related]
7. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.
Chen HY; Feng LL; Li M; Ju HQ; Ding Y; Lan M; Song SM; Han WD; Yu L; Wei MB; Pang XL; He F; Liu S; Zheng J; Ma Y; Lin CY; Lan P; Huang MJ; Zou YF; Yang ZL; Wang T; Lang JY; Orangio GR; Poylin V; Ajani JA; Wang WH; Wan XB
Oncologist; 2021 May; 26(5):e780-e793. PubMed ID: 33543577
[TBL] [Abstract][Full Text] [Related]
8. ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group.
Fleischmann M; Diefenhardt M; Nicolas AM; Rödel F; Ghadimi M; Hofheinz RD; Greten FR; Rödel C; Fokas E;
Clin Transl Radiat Oncol; 2022 May; 34():99-106. PubMed ID: 35449546
[TBL] [Abstract][Full Text] [Related]
9. Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial.
Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Fleischmann M; Fokas E; Rödel C
Radiother Oncol; 2021 Nov; 164():223-231. PubMed ID: 34619239
[TBL] [Abstract][Full Text] [Related]
10. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
Hofheinz RD; Arnold D; Fokas E; Kaufmann M; Hothorn T; Folprecht G; Fietkau R; Hohenberger W; Ghadimi M; Liersch T; Grabenbauer GG; Sauer R; Rödel C; Graeven U;
Ann Oncol; 2018 Aug; 29(8):1793-1799. PubMed ID: 29873684
[TBL] [Abstract][Full Text] [Related]
11. Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials.
von den Grün JM; Hartmann A; Fietkau R; Ghadimi M; Liersch T; Hohenberger W; Weitz J; Sauer R; Wittekind C; Ströbel P; Rödel C; Fokas E;
Radiother Oncol; 2018 Sep; 128(3):557-563. PubMed ID: 29929861
[TBL] [Abstract][Full Text] [Related]
12. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Rödel C; Fokas E
JAMA Oncol; 2020 Sep; 6(9):1416-1421. PubMed ID: 32644104
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of neoadjuvant rectal score in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and construction of a prediction model.
Sun Y; Zhang Y; Wu X; Lin H; Lu X; Huang Y; Xu Z; Huang S; Wang X; Chi P
J Surg Oncol; 2018 Mar; 117(4):737-744. PubMed ID: 29228455
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Rödel C; Martus P; Papadoupolos T; Füzesi L; Klimpfinger M; Fietkau R; Liersch T; Hohenberger W; Raab R; Sauer R; Wittekind C
J Clin Oncol; 2005 Dec; 23(34):8688-96. PubMed ID: 16246976
[TBL] [Abstract][Full Text] [Related]
16. Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
Kitz J; Fokas E; Beissbarth T; Ströbel P; Wittekind C; Hartmann A; Rüschoff J; Papadopoulos T; Rösler E; Ortloff-Kittredge P; Kania U; Schlitt H; Link KH; Bechstein W; Raab HR; Staib L; Germer CT; Liersch T; Sauer R; Rödel C; Ghadimi M; Hohenberger W;
JAMA Surg; 2018 Aug; 153(8):e181607. PubMed ID: 29874375
[TBL] [Abstract][Full Text] [Related]
17. Combined Detection of RUNX3 and EZH2 in Evaluating Efficacy of Neoadjuvant Therapy and Prognostic Value of Middle and Low Locally Advanced Rectal Cancer.
Wang L; Wu X; Xu W; Gao L; Wang X; Li T
Front Oncol; 2022; 12():713335. PubMed ID: 35280723
[TBL] [Abstract][Full Text] [Related]
18. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
19. Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter study.
Shaish H; Aukerman A; Vanguri R; Spinelli A; Armenta P; Jambawalikar S; Makkar J; Bentley-Hibbert S; Del Portillo A; Kiran R; Monti L; Bonifacio C; Kirienko M; Gardner KL; Schwartz L; Keller D
Eur Radiol; 2020 Nov; 30(11):6263-6273. PubMed ID: 32500192
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials.
George TJ; Allegra CJ; Yothers G
Curr Colorectal Cancer Rep; 2015; 11(5):275-280. PubMed ID: 26321890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
